Long-term outcome of primary glaucoma triple procedure with adjunctive 5-fluorouracil

Abstract

The use of low-dose subconjunctival 5-FU (mean dosage of 24.8 mg in 5.0 +/- 1.3 injections) as an adjunct did not significantly improve the long-term filtration outcome of PGTP in POAG patients.

Seven-year follow-up of combined cataract extraction and viscocanalostomy

“…25 Although long-term studies of phacotrabeculectomy with MMC report a mean pressure drop of 34% (to a mean IOP of 15 mm Hg) with MMC 2,26 and a pressure drop of 25% to 16 mm Hg with 5-fluorouracil, 27 these pressure levels were only achieved with the addition of a mean 1.0 medication per eye. We achieved a mean 33.2% pressure drop to a mean IOP of 16 mm Hg with virtually no medications (0.1 G 0.5).…”

Antiproliferative effect of mycophenolate mofetil on cultured human Tenon fibroblasts

“…Histologic examination of MMC-treated drainage blebs showed that the overlying treated area was virtually devoid of fibroblasts [45]. The clinical effect of the antimetabolites MMC and 5-FU has been well documented in many studies [3,7,42]. Many other antiproliferatives, such as mithramycin, daunorubicin and bleomycin [29], have been mainly investigated for in vitro use.…”

Antifibrotic effects of pirfenidone on Tenon’s fibroblasts in glaucomatous eyes: comparison with mitomycin C and 5-fluorouracil

“…Although these agents may inhibit fibrosis and increase the success rate of surgery [4,7,8], highrisk patients with a history of long-term medication use or those who take multiple IOP-lowering medications or who have severe inflammation still show poor long-term surgical outcome [9]. In addition, administration of these antimetabolites can cause serious complications such as corneal decompensation, bleb leakage, hypotonous maculopathy, retinal bleeding, ciliary toxicity, and infective endophthalmitis [10][11][12][13][14][15][16][17].…”